爱特医疗

最新新闻

• 评级变动
  Stifel Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/7/24
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Prime Medicine, Inc. (PRME) and Community Health (CYH)
  TipRanks · 2026/7/24
• 评级变动
  UBS Initiates AtriCure(ATRC.US) With Buy Rating, Announces Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• 评级变动
  Needham Initiates AtriCure(ATRC.US) With Buy Rating, Announces Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  Piper Sandler Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/7/24
• 评级变动
  Needham Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/7/24
• 评级变动
  Oppenheimer Maintains AtriCure(ATRC.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/24
• 评级变动
  BTIG Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/7/24
• BTIG Maintains AtriCure(ATRC.US) With Buy Rating, Raises Target Price to $55
  \u5e02\u573a\u8d44\u8baf · 2026/8/24
• Stifel Maintains AtriCure(ATRC.US) With Buy Rating, Raises Target Price to $65
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• Piper Sandler Maintains AtriCure(ATRC.US) With Buy Rating, Raises Target Price to $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• Freedom Capital Markets Downgrades AtriCure(ATRC.US) to Hold Rating, Raises Target Price to $57
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  BTIG Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $54
  \u5e02\u573a\u8d44\u8baf · 2026/2/18
• 评级变动
  BTIG Maintains AtriCure(ATRC.US) With Buy Rating, Cuts Target Price to $45
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Atricure (ATRC) and Tempus AI, Inc. Class A (TEM)
  TipRanks · 2026/5/6
• 评级变动
  CCORF Maintains AtriCure(ATRC.US) With Buy Rating, Raises Target Price to $55
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (ATRC), Q32 Bio (QTTB) and Shoulder Innovations, Inc. (SI)
  TipRanks · 2026/3/11
• 评级变动
  CCORF Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• Needham Maintains AtriCure(ATRC.US) With Buy Rating, Raises Target Price to $64
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 评级变动
  A Quick Look at Today's Ratings for AtriCure(ATRC.US), With a Forecast Between $45 to $55
  \u5e02\u573a\u8d44\u8baf · 2026/2/18

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。